DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of “Moderate Buy” from Brokerages

DBV Technologies S.A. (NASDAQ:DBVT) has received an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $48.50.

Several analysts have recently weighed in on DBVT shares. Weiss Ratings downgraded shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Guggenheim reaffirmed a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a research report on Monday, May 4th. Finally, Citizens Jmp upped their target price on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 30th.

Institutional Trading of DBV Technologies

Several institutional investors and hedge funds have recently made changes to their positions in the company. MPM Bioimpact LLC bought a new position in DBV Technologies during the 2nd quarter worth about $9,649,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of DBV Technologies in the 2nd quarter valued at about $9,659,000. Octagon Capital Advisors LP bought a new stake in shares of DBV Technologies in the 2nd quarter valued at about $9,315,000. Two Sigma Investments LP bought a new stake in shares of DBV Technologies in the 3rd quarter valued at about $167,000. Finally, Citadel Advisors LLC purchased a new stake in shares of DBV Technologies in the 3rd quarter worth approximately $220,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Price Performance

Shares of DBVT opened at $14.97 on Wednesday. DBV Technologies has a 1-year low of $8.70 and a 1-year high of $26.18. The company has a 50-day moving average of $14.91 and a 200 day moving average of $18.29. The firm has a market capitalization of $941.31 million, a price-to-earnings ratio of -4.26 and a beta of -0.93.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Thursday, July 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.48). The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.90 million. DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. On average, equities analysts anticipate that DBV Technologies will post -2.05 earnings per share for the current fiscal year.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.